NASDAQ:IRIX - IRIDEX Stock Price, Forecast & News

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings data on Thursday, November, 7th. The medical equipment provider reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.05. The medical equipment provider earned $10.66 million during the quarter, compared to analyst estimates of $10.08 million. IRIDEX had a negative return on equity of 37.78% and a negative net margin of 23.42%. View IRIDEX's Earnings History.

IRIDEX is scheduled to release their next quarterly earnings announcement on Tuesday, March 3rd 2020. View Earnings Estimates for IRIDEX.

IRIDEX issued an update on its FY 2019 After-Hours earnings guidance on Monday, November, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $$41-44 million, compared to the consensus revenue estimate of $$42.48 million.

2 brokers have issued 12-month target prices for IRIDEX's shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate IRIDEX's share price to reach $7.00 in the next year. This suggests a possible upside of 181.1% from the stock's current price. View Analyst Price Targets for IRIDEX.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IRIDEX.

News headlines about IRIX stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IRIDEX earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the company's share price in the near term. View News Stories for IRIDEX.

IRIDEX saw a decline in short interest during the month of November. As of November 15th, there was short interest totalling 77,700 shares, a decline of 93.8% from the October 31st total of 1,250,000 shares. Based on an average daily volume of 95,000 shares, the short-interest ratio is presently 0.8 days. Currently, 0.7% of the shares of the stock are sold short. View IRIDEX's Current Options Chain.

Some companies that are related to IRIDEX include Second Sight Medical Products (EYES), Soleno Therapeutics (SLNO), electroCore (ECOR), Fc Global Realty (FCRE), Precision Optics (PEYE), Helius Medical Technologies (HSDT), Reshape Lifesciences (RSLS), Nexeon Medsystems (NXNN), ENDRA Life Sciences (NDRA), Digirad (DRAD), Vaso (VASO), Non-Invasive Monitoring Systems (NIMU), CHF Solutions (CHFS), ReShape Lifesciences (RSLSD) and Viveve Medical (VIVE).

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include SCYNEXIS (SCYX), Agile Therapeutics (AGRX), CTI BioPharma (CTIC), Synergy Pharmaceuticals (SGYP), Trevena (TRVN), Allena Pharmaceuticals (ALNA), Capstone Turbine (CPST), Fate Therapeutics (FATE), Genocea Biosciences (GNCA) and Idera Pharmaceuticals (IDRA).

IRIDEX's stock is owned by many different of retail and institutional investors. Top institutional investors include Eidelman Virant Capital (0.86%), Perkins Capital Management Inc. (0.32%), Osborne Partners Capital Management LLC (0.19%) and Gabelli Funds LLC (0.15%). Company insiders that own IRIDEX stock include Associates & Paragon A Paragon, Robert Earle Grove, Romeo R Dizon, Scott Shuda and William M Moore. View Institutional Ownership Trends for IRIDEX.

IRIX stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc., Eidelman Virant Capital and Osborne Partners Capital Management LLC. View Insider Buying and Selling for IRIDEX.

IRIX stock was purchased by a variety of institutional investors in the last quarter, including Gabelli Funds LLC. Company insiders that have bought IRIDEX stock in the last two years include Associates & Paragon A Paragon, Robert Earle Grove, Scott Shuda and William M Moore. View Insider Buying and Selling for IRIDEX.

Shares of IRIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IRIX stock can currently be purchased for approximately $2.49.

IRIDEX has a market capitalization of $34.32 million and generates $42.60 million in revenue each year. The medical equipment provider earns $-12,810,000.00 in net income (profit) each year or ($1.05) on an earnings per share basis. View Additional Information About IRIDEX.

The official website for IRIDEX is http://www.iridex.com/.

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The medical equipment provider can be reached via phone at 650-940-4700 or via email at [email protected]